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The Ewing’s sarcoma (ES) family of tumors, including
peripheral neuroectodermal tumor (PNET), is defined
genetically by specific chromosomal translocations
resulting in fusion of the EWS gene with a member of
the ETS family of transcription factors, either FLI1
(90–95%) or ERG (5–10%). A second level of molecu-
lar genetic heterogeneity stems from the variation in
the location of the translocation breakpoints, result-
ing in the inclusion of different combinations of ex-
ons from EWS and FLI1 (or ERG) in the fusion prod-
ucts. The most common type of EWS-FLI1 fusion
transcript, type 1, is associated with a favorable prog-
nosis and appears to encode a functionally weaker
transactivator, compared to other fusion types. We
sought to determine whether the observed covaria-
tion of structure, function, and clinical course corre-
lates with tumor cell kinetic parameters such as pro-
liferative rate and apoptosis, and with expression of
the receptor for insulin-like growth factor I (IGF-1R).
In a group of 86 ES/PNET with defined EWS-ETS fu-
sions (45 EWS-FLI1 type 1, 27 EWS-FLI1 non-type 1,
14 EWS-ERG), we assessed proliferation rate by im-
munostaining for Ki-67 using MIB1 antibody (n 5 85),
apoptosis by TUNEL assay (n 5 66), and IGF-1R ex-
pression by immunostaining with antibody 1H7 (n 5
78). Ki-67 proliferative index was lower in tumors
with EWS-FLI1 type 1 than those with non-type 1
EWS-FLI1 , whether analyzed as a continuous (P 5
0.049) or categorical (P 5 0.047) variable. Logistic
regression analysis suggests that this association was
secondary to the association of type 1 EWS-FLI1 and
lower IGF-1R expression (P 5 0.04). Comparing EWS-
FLI1 to EWS-ERG cases, Ki-67 proliferative index was
higher in the latter (P 5 0.01, Mann-Whitney test; P 5
0.02, Fisher’s exact test), but there was no significant
difference in IGF-1R. TUNEL results showed no signif-
icant differences between groups. Our results suggest
that clinical and functional differences between alter-
native forms of EWS-FLI1 are paralleled by differences
in proliferative rate, possibly mediated by differential
regulation of the IGF-1R pathway. (Am J Pathol
2000, 156:849–855)
The Ewing’s sarcoma (ES) family of tumors, including
peripheral neuroectodermal tumor (PNET), represents a
clinicopathological entity with a variable neural differen-
tiation, usually appearing as a bone or soft tissue lesion in
a child or young adult. The primary genetic event is
chromosomal translocation resulting in fusion of the EWS
gene with a member of the ETS family of transcription
factors.1 The most frequent translocation partner of EWS
is FLI1 (90–95%), followed by ERG (5–10%). These fusion
products function as oncogenic aberrant transcription
factors.2 Detection of these fusions is considered to be
specific for ES/PNET, and has become a valuable tool for
the differential diagnosis of primitive small round cell
tumors.3,4
There is a considerable molecular genetic heteroge-
neity within ES/PNET. As mentioned above, either FLI1 or
ERG can rearrange with EWS in these gene fusions.
Furthermore, for either gene fusion, additional heteroge-
neity stems from the location of the genomic breakpoints
of the translocation, resulting in different combinations of
exons from EWS and FLI1 (or ERG).5 The most common
fusion joins EWS exon 7 in frame with FLI1 exon 6 (type 1
fusion). There are at least 12 other EWS-FLI1 types, and
at least 4 types of EWS-ERG fusion types described. We
and others6 have previously reported that among pa-
tients with EWS-FLI1 fusions, those having type 1 tran-
scripts have a better outcome regardless of conventional
prognostic factors such as stage, age, or tumor location.7
The biological mechanisms underlying this reproduc-
ible and significant association of fusion structure and
clinical behavior are unclear. As a first clue to how these
variables may be linked, we have recently found that the
EWS-FLI1 type 1 fusion may encode a transcription factor
with lower transactivation efficiency than other EWS-FLI1
fusion types.8 Because studies using various ap-
proaches to inhibit EWS-FLI1 function have shown that it
is a critical determinant of proliferation in ES/PNET cell
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lines,9–11 we have now sought to determine whether the
observed covariation of structure, function, and clinical
course extends to tumor cell kinetic parameters such as
proliferative rate and apoptosis. We have also examined
expression of the receptor for insulin-like growth factor 1
(IGF-1R), because there is evidence from several groups
implicating it in autocrine or paracrine control of ES/PNET
growth.12–15 The results of our analysis, described below,
are consistent with the notion that type 1 EWS-FLI1, func-
tionally a weaker transcription factor, may result in lesser
activation of direct or indirect target genes, possibly in-
cluding IGF-1R, controlling proliferative rate in ES/PNET.
Materials and Methods
Patients
We studied 86 patients with a histopathological diagnosis
of ES/PNET and molecular evidence of the EWS-FLI1 or
EWS-ERG fusion transcripts, 66 from the Memorial Sloan-
Kettering Cancer Center (MSKCC), 14 from Clı´nica Uni-
versitaria de Navarra (CUN), and 6 from the University of
Pennsylvania Medical Center/Children’s Hospital of Phil-
adelphia (UPMC/CHOP). Of 72 cases with the EWS-FLI1
fusion, 54 were included in our previous study.7 The 14
EWS-ERG cases, consisting of 7 MSKCC cases, 6 UPMC/
CHOP cases, and 1 case from CUN, were also included
in another study.16 EWS-ERG cases were actively sought
and therefore their proportion in the overall series (16%)
is not representative of their actual prevalence. There
were 55 males and 31 females. The mean age was 23
years (range, 5–72 years). Primary tumor dimensions
were available in 63 patients. Volume calculations for
bony (spheroidal) and soft tissue (spherical) tumors were
performed as described elsewhere.17 Mean and median
tumor volumes were, respectively, 456 ml and 72 ml.
Immunohistochemical and Apoptosis Analysis
All immunohistochemical and apoptosis analyses were
done on 4-mm sections of formalin-fixed, paraffin-embed-
ded, non-decalcified tumor. In 80 cases, prechemo-
therapy primary tumor was available for study, and in the
remaining 6 cases metastases were used as the source
of tumor. Immunohistochemistry was performed on an
automated immunostainer (TechMate 500; Dako, Copen-
hagen, Denmark) with the EnVision1 system (Dako), in
which the secondary antibody is coupled to a dextran
polymer linked to peroxidase. Endogenous peroxidase
activity was quenched by treatment with 5% hydrogen
peroxide in methanol for 30 minutes at room temperature.
Antigen retrieval by microwave treatment for 20 minutes
in an 800W microwave oven was performed. A blocking
step with normal rabbit serum was used. Primary antibod-
ies were applied for 120 minutes at room temperature.
Primary antibodies and dilutions were as follows: Ki-67
(MIB1 antibody, Zymed, South San Francisco, CA) 1/800
with microwave antigen retrieval, IGF-1R (1H7 antibody,
RDI, Flanders, NJ) 1/1200 with microwave retrieval and
trypsinization.
The sections were then rinsed with washing buffer at
room temperature. The next step was addition of EnVi-
sion1 system reagents and incubation 30 minutes at
room temperature. The slides were rinsed with washing
buffer, and treated with a solution containing 0.05% dia-
minobenzidine hydrochloride and 0.1% hydrogen perox-
ide in 0.05 mol/L Tris-buffered saline, pH 7.4, at room
temperature for 5 minutes. After rinsing in distilled water
for 3 minutes, the slides were counterstained with modi-
fied Harris hematoxylin, dehydrated, and mounted. For
negative controls, incubation with normal goat serum
instead of primary antibody was used. Omission of the
primary antibody likewise gave no background staining.
In situ detection of apoptosis by use of the terminal
deoxynucleotidyl transferase-mediated dUTP nick-end
labeling (TUNEL) technique was performed as previously
described using the ApopTag In Situ Apoptosis Detection
Kit (Intergen, Gaithersburg, MD) that identifies cells with
internucleosomal fragmentation of DNA. Sections from
selected formalin-fixed, paraffin-embedded tissue blocks
were placed on coated slides. Briefly, tissue sections
were dewaxed and rehydrated routinely. After rehydra-
tion, the slides were incubated with proteinase K (20
mg/ml) at room temperature for 15 minutes, per the man-
ufacturer’s protocol. Endogenous peroxidase was inacti-
vated by 3% hydrogen peroxide. Tissue sections were
then subjected to the ApopTag reaction. The reaction
was terminated after 60 minutes by transfer of the slides
to a coplin jar containing pre-warmed working strength
stop-wash buffer and incubated for 30 minutes at 37°C.
The sections were then covered with 55 ml of anti-digoxi-
genin-peroxidase and incubated for 30 minutes at room
temperature, and stained with diaminobenzidine to de-
tect the labeled nuclei. For negative controls, deionized
water was used instead of terminal deoxynucleotidyl
transferase. Positive controls consisted of inflamed hu-
man tonsil and acute myocardial infarction. Cells were
considered positive when brown reactivity was detected
in the nuclei.
Results of immunohistochemical and apoptosis assays
were evaluated by two independent observers (E. de A.
and A. P.) blinded to clinicopathological and molecular
data. Tissue sections were examined under high power
magnification (3400). The number of immunoreactive
cells was counted on three randomly selected fields, and
expressed as a percentage of cells. In tumors with het-
erogeneous distribution of the immunoreactivity, four ar-
eas with the highest and the lowest number of reactive
cells were counted and median value was reported.
Cases in which discrepancy between observers was
.15% were reviewed and a consensus was reached.
Molecular Study
The fusion transcripts in all but 18 cases had been char-
acterized in previous studies.7,16 Reverse transcriptase-
polymerase chain reaction (RT-PCR) for EWS-FLI1 and
EWS-ERG transcripts was performed on total RNA ex-
tracted from snap frozen tumor samples. EWS-FLI1 type
1 (7–6 fusion) and type 2 (7–5 fusion) products were
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typed according to the size of the RT-PCR products on
agarose gel electrophoresis. Other less common fusion
products were either blotted and probed with internal and
junction-specific probes, or sequenced. EWS-ERG fusion
transcripts were not subtyped for this analysis. Negative
controls lacking either tumor RNA or reverse transcrip-
tase were routinely used.
Statistical Analysis
Immunoreactivities with the different antibodies and ap-
optosis results were assessed as continuous variables.
Because number of immunoreactive cells did not follow a
normal distribution, we used Mann-Whitney nonparamet-
ric tests to compare qualitative (gene fusion type) with
quantitative parameters (immunoreactivity). Logistic re-
gression was used to study the univariate prognostic
value of each factor for predicting proliferation, measured
as Ki-67 index below or above the median value (15%).
Factors with a univariate P value of not more than 0.2 for
predicting Ki-67 index were considered in a multivariate
logistic regression. The two factors included in final lo-
gistic regression, EWS-FLI1 transcript type, and IGF-1R
expression were chosen to give the best two-factor
model among all of the factors considered. All analyses
were performed using SPSS statistical package, version
6.0 for Windows (SPSS, Inc. Chicago, IL). All P values
were two-tailed.
Results
Immunoreactivity for Ki-67 obtained with the MIB1 anti-
body had a nuclear pattern with strong nucleolar staining
(Figure 1). Immunostaining for Ki-67 was most frequently
seen in nuclei of dark cells, that seldom showed TUNEL
reactivity. In ES/PNET, cells with hyperchromatic nuclei
(dark cells) are usually seen along with cells having clear
nuclei. They have traditionally been regarded as apopto-
tic cells.18 Interestingly, nuclei reactive with the TUNEL
technique were usually those of clear cells, whereas
those of dark cells appeared positive less often. This
pattern of TUNEL reactivity in some clear cells could
represent an early stage of apoptosis, because the char-
acteristic morphological appearance of apoptotic nuclei
is a later event in the apoptotic process. Membranous
staining was seen with the antibody to IGF-1R (Figure 2).
Most cases showed widespread IGF-1R immunoreactiv-
ity and all cases contained at least some positive cells.
The mean and median percentages of tumor cells
positive for these markers were respectively as follows:
Ki-67 (n 5 85) 21% and 14%, IGF-1R (n 5 78) 73% and
80%, and TUNEL (n 5 66) 5% and 2%. There was a
significant positive correlation between proliferative index
as assessed by immunostaining for Ki-67, and IGF-1R
immunoreactivity (Spearman correlation coefficient, r 5
0.23; P 5 0.04). All cases with Ki-67 immunoreactivity in
.20% of tumor cells had IGF-1R expression in 50% or
more of cells (Figure 3). Conversely, all cases with ,40%
IGF-1R-positive cells had a Ki-67 proliferative index of
10% or less.
There were 72 tumors with EWS-FLI1 transcripts: 44
type 1 fusions and 28 grouped into the non-type 1 group.
Fourteen tumors had EWS-ERG fusions. Patients having
Figure 1. Ki-67 proliferation rate assesed by MIB1 immunohistochemistry in
ES/PNET. Left panel shows ES/PNET case with non-type 1 EWS-FLI1 and
high Ki-67. Right panel shows ES/PNET case with type 1 EWS-FLI1 and low
Ki-67.
Figure 2. IGF-1R immunohistochemistry in ES/PNET. ES/PNET case with
high IGF-1R expression is shown.
Figure 3. Scattergram showing correlation between Ki-67 (MIB1) and
IGF-1R immunoreactivities. Significant Ki-67 immunoreactivity (.10%) was
only present when over 50% of cells show expression of IGF-1R. Tumors
having non-type 1 EWS-FLI1 fusions (green triangles) had significantly
higher values of IGF-1R and Ki-67 (see Tables 1 and 2).
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EWS-FLI1 fusions had similar age, stage at diagnosis,
and tumor volume with respect to those bearing EWS-
ERG fusion genes (results not shown).
In the group of tumors with EWS-FLI1 transcripts, those
having type 1 fusions had a lower immunoreactivity for
Ki-67 (15%; P 5 0.049), and for IGF-1R (65%; P 5 0.015)
than tumors with other EWS-FLI1 fusion types (24% and
82%, respectively) by Mann-Whitney test (Table 1). In
aggregate, tumors with EWS-FLI1 transcripts had lower
values for Ki-67 (P 5 0.01) than those with EWS-ERG
fusions by Mann-Whitney test (Table 1).
We then analyzed Ki-67 proliferation index as a cate-
gorical variable by using 15%, essentially the median
Ki-67 value in the entire study group (see above), to
delineate low and high proliferation subgroups. By Fish-
er’s exact test, both the type 1 versus non-type 1 EWS-
FLI1 comparison (P 5 0.047; Table 2) and the EWS-FLI1
versus EWS-ERG comparison (P 5 0.02; Table 3) re-
mained statistically significant.
To further dissect the relative contributions of these
variables to proliferation index in ES/PNET, we performed
a logistic regression analysis of factors determining Ki-
67. In an analysis including EWS-FLI1 type 1 versus non-
type 1 and IGF-1R, the latter remained significant (P 5
0.049), but EWS-FLI1 transcript type was no longer sig-
nificant (P 5 0.3), suggesting that the impact of the latter
on Ki-67 values may be due largely to its correlation with
IGF-1R expression.
No significant correlations were seen between Ki-67 or
transcript type and stage at diagnosis or tumor volume.
Tumors metastatic at diagnosis were larger than those
presenting with localized disease only (1390 ml vs. 242
ml respectively; P 5 0.001). No other correlations were
identified among the parameters studied. There were no
significant differences in the proportion of apoptotic cells,
as detected by the TUNEL assay, among the groups.
Discussion
The consistent involvement of transcription factors in the
gene fusions observed in many small cell sarcomas sug-
gests a central role for these proteins in the regulation of
proliferation and differentiation of mesenchymal cells.19
EWS-FLI1 is an aberrant transcription factor, and exper-
imental evidence suggests that EWS-FLI1 initiates and
maintains tumorigenicity in ES/PNET.2 Indeed, specific
inactivation of EWS-FLI1 in ES/PNET cell lines results in
reduced proliferation and loss of tumorigenicity.9–11
Ki-67 is expressed in late G1, S, G2, and M phases,
and hence correlates closely with growth fraction in all
tumor types.20 Although its function is not well known,
nuclear overexpression of Ki-67 has been associated
with tumor progression and poor prognosis in many dif-
ferent tumors, including sarcomas.21–24 There have been
few systematic studies of proliferation markers in ES/
PNET. Our median Ki-67 value with the MIB1 antibody
(14%) was slightly higher than the range of proliferative
rates previously reported for this tumor (7–10%) using
other techniques.25–28 The significant positive correlation
between proliferative rate and IGF-1R expression level
(P 5 0.04) found in the present study is consistent with
the known cellular biology of IGF-1R29,30 and supports
the validity of the immunohistochemical methods used to
evaluate these two parameters.
Our Ki-67 data, whether analyzed as continuous or
categorical variables, suggest that tumors with EWS-FLI1
type 1 have, on average, a lower proliferative rate than
ES/PNET with non-type 1 EWS-FLI1. Our logistic regres-
sion analysis further suggests that the partial association
of type 1 EWS-FLI1 and lower IGF-1R expression may
account at least in part for the association of Ki-67 and
EWS-FLI1 fusion type.
IGF-1R is widely expressed by proliferating cells
throughout development.29,30 IGF-1 and its receptor,
IGF-1R, are expressed in many human tumors,29,30 in-





non-type 1 P value*
EWS-FLI1
(all types) EWS-ERG P value*
TUNEL 2.4 6 0.4 5.3 6 3.6 0.49 3.5 6 1.4 10.1 6 5.9 0.3
(n 5 66)
Ki-67 15 6 2 24 6 4 0.049 18 6 2 35 6 8 0.01
(n 5 85) median, 12 median, 20 median, 13 median, 23
IGF-1R 65 6 5 82 6 4 0.015 72 6 3 79 6 5 0.58
(n 5 78) median, 73 median, 85 median, 80 median, 80
*Mann-Whitney test.
Values correspond to mean percentage value of immunoreactive cells 6 SE.
Table 2. Comparison of Ki-67 Results as Categorical







Ki-67 , 15% 30 11
Ki-67 . 15% 15 16
P 5 0.047, Fisher’s exact test.
Values correspond to number of cases.
Table 3. Comparison of Ki-67 Results as Categorical
Variables, EWS-FLI1 vs. EWS-ERG
Category EWS-FLI1* EWS-ERG*
Ki-67 , 15% 41 3
Ki-67 . 15% 31 11
P 5 0.02, Fisher’s exact test.
Values correspond to number of cases.
*all types.
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cluding various sarcomas.31 In at least some ES/PNET,
they appear to constitute a functional autocrine or para-
crine loop.12,14 Blockade of IGF-1R stops proliferation
and induces apoptosis in ES/PNET.12–14 Consistent with
these studies, we found a significant positive correlation
in ES/PNET between Ki-67 proliferative index and the
proportion of cells expressing IGF-1R. Tumors with EWS-
FLI1 Type 1 fusions had significantly fewer cells immuno-
reactive for IGF-1R. The simplest model accounting for
these associations of fusion type, IGF-1R expression, and
proliferative rate would suggest that the IGF-1R gene is a
direct or indirect target of EWS-FLI1 and therefore sub-
ject to differential regulation by alternative forms of this
aberrant transcription factor.8 Few regulatory targets of
EWS-FLI1 or native FLI1 have so far been identified.32–35
There are contradictory data on IGF-1R regulation by
EWS-FLI1. In a study recently reported in abstract form,
Shum et al36 found IGF-1R gene expression to be de-
creased following induction of EWS-FLI1 in a human em-
bryonal kidney cell line (EcR293). On the other hand,
Toretsky et al reported no significant difference in endog-
enous IGF-1R protein levels in mouse fibroblast cell lines
with or without stably transfected human EWS-FLI1,37
leading them to conclude that IGF-1R expression is not
regulated by the fusion protein. Whether these experi-
mental models are representative of IGF-1R regulation in
ES/PNET is unclear, however. The human and murine
IGF-1R promoter regions are not identical, and mouse
fibroblasts, human embryonal kidney cells, and human
ES/PNET cells may differ in cell type-specific transcrip-
tional cofactors.
We found all cases to show at least some IGF-1R
expression by immunohistochemistry. This is consistent
with its ubiquity at the mRNA or protein level in ES/PNET
cell lines or clinical samples as shown by others.12,14
Evidence that IGF-1R expression is required for EWS-
FLI1 transformation of mouse fibroblasts37 suggests that
in vivo, this fusion protein may have a similar requirement
for a IGF-1R-positive precursor cell or for induction of the
IGF-1R pathway. Although essentially all cases showed
at least some IGF-1R expression, its level could be criti-
cal for maintaining cell proliferation in ES/PNET, because
only cases with .40% of cells expressing IGF-1R had a
significant Ki-67 immunoreactivity (.10%; see Figure 3).
The differences in extent of IGF-1R immunoreactivity be-
tween type 1 and non-type 1 EWS-FLI1 groups, although
statistically significant (P 5 0.015), were relatively small
(65% vs. 82%). Nonetheless, there is experimental evi-
dence that small differences in IGF-1R expression level
per cell can effectively modulate cell proliferation.38
We have recently reported in a partially overlapping
series that tumors with EWS-ERG fusions have a similar
clinical presentation and behavior as those with EWS-
FLI1 chimeric genes.16 It may thus be unexpected that
there was a difference in proliferative index, as assessed
by Ki-67 immunoreactivity, between these two groups.
No differences in IGF-1R expression were seen between
EWS-FLI1 and EWS-ERG cases, suggesting that the ob-
served difference in proliferative rate could be due to
differential activation of other target pathways. The extent
to which activation of downstream targets may differ
quantitatively or qualitatively between EWS-FLI1 and
EWS-ERG is unknown. Indeed, outside their DNA-binding
domains, FLI1 and ERG show major sequence differ-
ences which could be significant in the protein-protein
interactions involved in the regulation of certain promot-
ers. It is therefore not unreasonable to consider the pos-
sibility that EWS-FLI1 and EWS-ERG may deregulate
some partly non-overlapping pathways to generate clin-
ical phenotypes which are so far indistinguishable.
Because both EWS-FLI1 and EWS-ERG fusion proteins
have been shown to inhibit apoptosis in model sys-
tems,39 we were interested in comparing relative num-
bers of apoptotic cells in these pretreatment clinical sam-
ples. However, the numbers of apoptotic cells shown by
the TUNEL technique were small and there were no sig-
nificant differences among the fusion types.
Other determinants of proliferation rate may include
secondary genetic alterations in cell cycle regulators. In
two series of ES/PNET which partially overlapped with the
present study group, we have found evidence of P53
alterations in 11% and INK4A deletion in 17%.40,41 Similar
percentages have been reported by other groups.42–48
These genetic alterations are relatively uncommon but
appear prognostically significant.40,41,48 Because of their
low prevalence, however, alterations in cell cycle regula-
tors are unlikely to account for the significant differences
in Ki-67 values between groups in the present study, but
may explain some of the variability in proliferative rate
within these groups. Establishing whether the distribution
of these secondary genetic alterations in cell cycle reg-
ulators is random in relation to EWS-ETS fusion type will
require a much larger systematic multiparameter study.
In summary, the most common type of EWS-FLI1 fusion
transcript, type 1, is associated with a favorable progno-
sis6,7 and appears to encode a functionally weaker trans-
activator8 compared to other fusion types. The present
study indicates that these differences are paralleled by
similar differences in proliferative rate, perhaps mediated
in part by the putative differential regulation of the IGF-1R
pathway by these alternative forms of EWS-FLI1. Further
elucidation of the target genes of EWS-FLI1 should clarify
this intriguing aspect of the biology of ES/PNET.
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